Oncology NEWS International Vol 17 No 1

New tobacco product alert: Camel Snus is on the loose

January 01, 2008

Imagine my surprise to unwrap my Sunday paper one day last month and find inside a clever advertising pamphlet and a card good for a free tin of Camel Snus (pronounced "snoose"), R.J. Reynolds' new flavored spitless chewing tobacco.

Blueberry punch not quite a 'knock out' blow

January 01, 2008

Presentations at the AACR's Frontiers in Cancer Prevention conference, showed both the promise and pitfalls of attempts to move complementary approaches from the fringes to the front of cancer care (see also pages 18 and 20). One of the dangers when looking at early complementary research is the risk of overinterpreting preliminary results

Texas voters listen to Lance

January 01, 2008

Proposition 15, which passed by a margin of 61% to 39% last November, provides for the creation of the Cancer Prevention and Research Institute of Texas and authorizes issuance of up to $3 billion in bonds for research in Texas to find the causes of and cures for cancer.

High cost of breast MRI screening appears to be justified

January 01, 2008

MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the United States if new American Cancer Society guidelines

Steven Rosen, MD, accepts Editor-in-Chief position for Oncology News International

January 01, 2008

Steven Rosen, MD, Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, and director of the Robert H. Lurie Comprehensive Cancer Center, has agreed to accept the position of Editor-in-Chief for Oncology News International (ONI).

Major policy issue lies behind ODAC's Avastin decision

January 01, 2008

By a 5-4 vote, the Oncology Drugs Advisory Committee failed to recommend that FDA approve Avastin (bevacizumab, Genentech) in combination with paclitaxel as a first-line treatment for locally recurrent or metastatic, HER2-negative breast cancer.

Zevalin boosts PFS in advanced follicular NHL patients

January 01, 2008

Consolidation therapy using Zevalin (90yttrium-ibritumomab tiuxetan) following first remission significantly extends progression-free survival in patients with advanced-stage follicular non-Hodgkin's lymphoma

Researchers defend NLST protocol against its critics

January 01, 2008

The first interim results from the first study of dasatinib (Sprycel) as induction therapy of Ph+ acute lymphoblastic leukemia (ALL) show complete and early hematologic responses with good overall compliance

High-dose neoadjuvant fulvestrant tested

January 01, 2008

In the neoadju-vant treatment of early breast cancer, fulvestrant (Faslodex) 500 mg effected a greater reduction in biomarkers of proliferation and produced more responses than the standard 250 mg dose

African Americans have higher risk of relapse after BCT

January 01, 2008

African-American women with early-stage breast cancer are more likely than their Caucasian counterparts to experience a relapse after breast-conserving therapy, but the absolute difference in risk is small

Anthracyclines in early breast ca: Is the end near?

January 01, 2008

Studies presented at the 2007 San Antonio Breast Cancer Symposium raise new questions about the role of anthracycline-based regimens as adjuvant therapy in early breast cancer, suggesting that these regimens may be appropriate only for a small subset of patients.

Cost-shifting could sink healthcare system

January 01, 2008

Soaring expenditures must be contained or they will end up sinking the healthcare system, Allen S. Lichter, MD, CEO of ASCO, said during a featured appearance at the Radiological Society of North America meeting (see photograph below). Among the changes that could help attack the problem is mandatory insurance coverage for all citizens, Dr. Lichter said. He also cast doubt on the ability of one currently popular approach, consumer-driven, high-deductible healthcare plans, to solve the system's problems.

Dasatinib promising as induction therapy of Ph+ ALL

January 01, 2008

The first interim results from the first study of dasatinib (Sprycel) as induction therapy of Ph+ acute lymphoblastic leukemia (ALL) show complete and early hematologic responses with good overall compliance

Microarray Technology Aids in Breast Cancer Prognosis

January 01, 2008

A cutting-edge prognostic tool called MammaPrint, developed by Agendia, a laboratory located in The Netherlands, uses molecular technology to predict whether breast cancer will metastasize, helping clinicians make more accurate management decisions for their patients.

PET provides clues to improving lung cancer radiotherapy

January 01, 2008

Positron emission tomography (PET) can be used to better characterize patterns of local failure after definitive radiation therapy for non-small-cell lung cancer, which may help to improve that therapy

RT improves outcomes of early-stage DLBCL patients

January 01, 2008

Patients with early-stage diffuse large B-cell lymphoma (DLBCL) have improved long-term disease-free and overall survival if their first-line treatment includes radiation therapy, according to the largest outcomes study to date among this population.

Good results with multicatheter brachytherapy APBI

January 01, 2008

Use of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to treat resected early-stage breast cancer is associated with good early outcomes in terms of local control, adverse effects, and cosmesis

Cetuximab efficacy does not vary with EGFR expression

January 01, 2008

The efficacy of cetuximab (Erbitux) plus chemoradiation in patients with locally advanced non-small-cell lung cancer does not appear to vary with the tumor's epidermal growth factor receptor expression, according to preliminary results of a phase II trial

Black raspberries may protect against esophageal ca

January 01, 2008

Extracts of black raspberries might protect Barrett's esophagus patients against esophageal cancer and also might shift premalignant oral lesions from progression to squamous cell carcinoma (SCC) back toward normal differentiation

Diagnostic Dilemma: GI Disease

January 01, 2008

A 68-year-old man with a history of small-cell lung cancer with bony metastases was admitted with diarrhea. The patient had completed chemotherapy one week earlier with cisplatin and etoposide, along with radiation therapy, and irinotecan (Camptosar). The patient was found to be neutropenic.